Olanzapine-induced ketoacidosis with diabetes mellitus.
Lindenmayer
J P
JP
Patel
R
R
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000987:Antisocial Personality Disorder / Q000188:drug therapy; D001569:Benzodiazepines; D003920:Diabetes Mellitus / Q000139:chemically induced*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine